GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines
February 08 2023 - 9:00AM
via NewMediaWire
– GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced
significant progress in developing a high-yield, high-capacity,
continuous avian cell line system for manufacturing its MVA
(modified vaccinia Ankara)-based vaccines and
immunotherapies.
Currently, MVA vaccines are manufactured in cells cultured from
chicken embryonic fibroblasts (CEF), a suboptimal and
time-consuming process useful primarily for niche markets and
stockpile reserves. Now, after exploring various approaches to
growing MVA in continuous cell lines in bioreactors more suitable
for high-yield, commercial-scale manufacturing, GeoVax will
accelerate activities towards fully implementing a proprietary,
continuous cell line manufacturing system that will provide
lower-cost, scalable versatility for broad MVA vaccine and
immunotherapy applications.
During his presentation at the BIO CEO and Investor Conference
in New York City, David Dodd, President and CEO, stated,
“Developing a high-yield, high-capacity process to produce
MVA-based vaccines and immunotherapies will be nothing short of
transformational – for GeoVax, biomedicine, and the public’s
health. By advancing our MVA manufacturing to a modern,
interchangeable process, we are on course to expand MVA
applications from stockpile-based solutions for niche medical
markets to respond to world needs on a timely basis, whenever and
wherever they arise. We believe that GeoVax will be the first
supplier of MVA-based vaccines to implement such a transformative
manufacturing process. We also intend to become the first
U.S.-based supplier of the MVA vaccine to prevent Mpox (monkeypox),
Smallpox and other pox-related viruses.”
About GeoVaxGeoVax Labs, Inc. is a clinical-stage
biotechnology company developing novel therapies and vaccines for
cancers and many of the world’s most threatening infectious
diseases. The company’s lead program in oncology is a novel
oncolytic solid tumor gene-directed therapy, Gedeptin®, presently
in a multicenter Phase 1/2 clinical trial for advanced head and
neck cancers. GeoVax’s lead infectious disease candidate is
GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk
immunocompromised patient populations. Currently in two Phase 2
clinical trials, GEO-CM04S1 is being evaluated as a single-dose
COVID-19 vaccine for immunocompromised patients such as those
suffering from hematologic cancers and other patient populations
for whom the current authorized COVID-19 vaccines are insufficient.
In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating
the vaccine as a more robust, durable COVID-19 booster among
healthy patients who previously received the mRNA vaccines. GeoVax
has a leadership team who has driven significant value creation
across multiple life science companies over the past several
decades. For more information, visit our website:
www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding
GeoVax’s business plans. The words “believe,” “look forward to,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,”
“plan,” “could,” “target,” “potential,” “is likely,” “will,”
“expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is contained in our
periodic reports on Form 10-Q and Form 10-K that we have filed and
will file with the SEC. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
Media Relations Contact:Nancy
TurettGeoVax914-434-0311nmturett@geovax.com
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From May 2024 to Jun 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jun 2023 to Jun 2024